Smartly-engineered monoclonal antibody-based therapeutics

opening opportunities for new biologic activities by the simultaneous targeting of multiple pathways.

Learn more about our Zybody™ platform

Developing a new class of biotherapeutics

that address the complexity of diseases.

Learn more about Zyngenia

Addressing unmet needs in cancer, inflammation and autoimmune disorders

Learn more about our development programs

More comprehensive disease intervention

with the cost and development paradigm of a single biologic agent.

Learn more about partnership opportunities